- Home
- RMAX vs NTHI Comparison
RMAX vs NTHI Comparison
Compare RMAX & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- NTHI
- Stock Information
- Founded
- RMAX 1973
- NTHI 2008
- Country
- RMAX United States
- NTHI United States
- Employees
- RMAX N/A
- NTHI N/A
- Industry
- RMAX Real Estate
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- RMAX Finance
- NTHI Health Care
- Exchange
- RMAX Nasdaq
- NTHI Nasdaq
- Market Cap
- RMAX 151.5M
- NTHI 142.5M
- IPO Year
- RMAX 2013
- NTHI N/A
- Fundamental
- Price
- RMAX $7.44
- NTHI $7.12
- Analyst Decision
- RMAX Hold
- NTHI
- Analyst Count
- RMAX 2
- NTHI 0
- Target Price
- RMAX $9.75
- NTHI N/A
- AVG Volume (30 Days)
- RMAX 155.1K
- NTHI 95.7K
- Earning Date
- RMAX 05-01-2025
- NTHI 01-01-0001
- Dividend Yield
- RMAX N/A
- NTHI N/A
- EPS Growth
- RMAX N/A
- NTHI N/A
- EPS
- RMAX 0.44
- NTHI N/A
- Revenue
- RMAX $303,865,000.00
- NTHI $79,990.00
- Revenue This Year
- RMAX N/A
- NTHI N/A
- Revenue Next Year
- RMAX $1.59
- NTHI N/A
- P/E Ratio
- RMAX $16.65
- NTHI N/A
- Revenue Growth
- RMAX N/A
- NTHI 13.52
- 52 Week Low
- RMAX $6.90
- NTHI $4.11
- 52 Week High
- RMAX $14.31
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- RMAX 42.98
- NTHI N/A
- Support Level
- RMAX $7.15
- NTHI N/A
- Resistance Level
- RMAX $7.63
- NTHI N/A
- Average True Range (ATR)
- RMAX 0.22
- NTHI 0.00
- MACD
- RMAX -0.01
- NTHI 0.00
- Stochastic Oscillator
- RMAX 33.17
- NTHI 0.00
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").